Last $1,154 MXN
Change Today +5.90 / 0.51%
Volume 3.9K
GILD* On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:09 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD*) Snapshot

Open
$1,157
Previous Close
$1,149
Day High
$1,161
Day Low
$1,154
52 Week High
07/14/14 - $1,170
52 Week Low
08/15/13 - $732.00
Market Cap
1.8T
Average Volume 10 Days
6.7K
EPS TTM
--
Shares Outstanding
1.5B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GILEAD SCIENCES INC (GILD*)

gilead sciences inc (GILD*) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

6,100 Employees
Last Reported Date: 02/25/14
Founded in 1987

gilead sciences inc (GILD*) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $746.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $884.2K
Senior Advisor
Total Annual Compensation: $810.4K
Compensation as of Fiscal Year 2013.

gilead sciences inc (GILD*) Key Developments

Gilead Sciences, Inc. Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C

Gilead Sciences Inc. announced that the company has submitted a New Drug Application (NDA) to Japan's Pharmaceutical and Medical Devices Agency (PMDA) for approval of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The data in the NDA support the use of sofosbuvir with ribavirin (RBV) for 12 weeks in patients with genotype 2 HCV infection. If approved, sofosbuvir would form the basis of the first all-oral, interferon-free treatment regimen for genotype 2 patients in Japan. The NDA is based primarily on data from a Phase 3 clinical trial conducted in Japan (Study GS-US-334-0118) among 153 treatment-naïve and treatment-experienced genotype 2 patients. In the study, 97% (n=148/153) of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV 600--1,000 mg/day achieved a sustained virologic response 12 weeks after completing therapy (SVR12). Patients who achieve SVR12 are considered cured of HCV infection. The NDA is also supported by SVR12 results from four international Phase 3 studies (FISSION, FUSION, POSITRON and VALENCE), which included genotype 2 HCV patients.

Gilead Sciences, Inc. Announces Results from Phase III Hepatitis C Virus Trial

Gilead Sciences Inc. has announced results from a Phase III clinical trial in Japan evaluating the investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir, or LDV, 90mg and the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, 400mg, with and without ribavirin, or RBV, for the treatment of genotype 1 chronic hepatitis C virus, or HCV, infection. Among patients receiving 12 weeks of LDV/SOF without RBV, 100% (n=83/83) of treatment-naive and 100% (n=88/88) of treatment-experienced patients achieved a sustained virologic response 12 weeks after completing therapy (SVR12). Among patients receiving LDV/SOF plus RBV, 96% (n=80/83) of treatment-naïve and 100% of treatment-experienced patients (n=87/87) achieved SVR12. Across all arms of the study, patients with cirrhosis achieved a 99% (n=75/76) SVR12. The study met its primary endpoint of superiority compared to a predefined historical SVR12 rate. Patients who achieve SVR12 are considered cured of HCV infection. In the study, 341 patients with genotype 1 HCV infection were randomized to receive 12 weeks of all-oral therapy with LDV/SOF, with or without RBV. Of these, 166 patients were treatment-naive, 175 were treatment-experienced and 76 had compensated cirrhosis. Overall, 338/341 patients in Study GS-US-337-0113 achieved SVR12. Of the three patients who failed to achieve SVR12, one patient relapsed after discontinuation of therapy, one patient discontinued therapy after one week of treatment due to rash and one patient died during the study. Fewer adverse events were observed in the RBV-free arms compared to the RBV-containing arms in the study, most notably with regard to anemia, which was observed in 14% of patients taking LDV/SOF plus RBV compared to 2% of patients receiving LDV/SOF alone. Adverse events observed with LDV/SOF without RBV were generally mild.

Shire Is In Spotlight Today

Shire plc (LSE:SHP) is into spotlight today for a international takeover. An insider said that Shire was anticipating at least one acquisition approach in 2014. Bristol-Myers Squibb Company (NYSE:BMY), Biogen Idec Inc. (NasdaqGS:BIIB), Amgen Inc. (NasdaqGS:AMGN), Abbvie Inc. (NYSE:ABBV) and Gilead Sciences Inc. (NasdaqGS:GILD) could be the potential buyers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD*:MM $1,154.40 MXN +5.90

GILD* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.00 USD -0.91
Amgen Inc $119.03 USD +0.73
AstraZeneca PLC 4,397 GBp +6.50
Bristol-Myers Squibb Co $48.92 USD -0.20
Eli Lilly & Co $63.64 USD +0.17
View Industry Companies
 

Industry Analysis

GILD*

Industry Average

Valuation GILD* Industry Range
Price/Earnings 33.1x
Price/Sales 10.0x
Price/Book 10.2x
Price/Cash Flow 29.9x
TEV/Sales 8.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.